AR102227A1 - Triazolopirazinonas como inhibidores de pde1 - Google Patents
Triazolopirazinonas como inhibidores de pde1Info
- Publication number
- AR102227A1 AR102227A1 ARP150103269A ARP150103269A AR102227A1 AR 102227 A1 AR102227 A1 AR 102227A1 AR P150103269 A ARP150103269 A AR P150103269A AR P150103269 A ARP150103269 A AR P150103269A AR 102227 A1 AR102227 A1 AR 102227A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- group
- compound
- twice
- formula
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000003566 oxetanyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Substances 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- MIUVADXDHCPQCD-UHFFFAOYSA-N 7h-[1,2,4]triazolo[4,3-a]pyrazin-8-one Chemical group O=C1NC=CN2C=NN=C12 MIUVADXDHCPQCD-UHFFFAOYSA-N 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- -1 methyl-3-propyl Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto que tiene la estructura del compuesto de fórmula (1) donde n es 0 ó 1; R¹ se selecciona a partir del grupo constituido por alquilo C₁₋₈ lineal o ramificado, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo y cicloalquilo C₃₋₈ monocíclico saturado; o R¹ se selecciona a partir del grupo constituido por oxetanilo sustituido una o dos veces con metilo o hidroxi; tetrahidrofuranilo sustituido una o dos veces con metilo o hidroxi; tetrahidropiranilo sustituido una o dos veces con metilo o hidroxi; cicloalquilo C₃₋₈ monocíclico saturado sustituido una o dos veces con metilo o hidroxi; y alquilo C₁₋₈ lineal o ramificado sustituido una, dos o tres veces con flúor; y R² se selecciona a partir del grupo constituido por alquilo C₁₋₈ lineal o ramificado, fenilo, cicloalquilo C₃₋₈ monocíclico saturado, cicloalquilo C₄₋₁₀ bicíclico saturado, cicloalquilo C₇₋₁₀ tricíclico saturado, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo; o R² se selecciona a partir del grupo constituido por fenilo sustituido con un sustituyente seleccionado a partir del grupo constituido por halógeno, metilo, difluorometilo, trifluorometilo y metoxi; cicloalquilo C₃₋₈; monocíclico saturado, sustituido una o dos veces con sustituyentes seleccionados a partir del grupo constituido por flúor y metilo; y oxetanilo, tetrahidrofuranilo y tetrahidropiranilo, cada uno sustituido una o dos veces con sustituyentes seleccionados a partir del grupo constituido por flúor y metilo; R³ se selecciona a partir del grupo constituido por alquilo C₁₋₄ lineal o ramificado, fenilo, fenilo sustituido, halógeno y tetrahidrofuranilo; R⁴ se selecciona a partir del grupo constituido por alquilo C₁₋₄ lineal o ramificado, halógeno y tetrahidrofuranilo; y sales de adición de ácido farmacéuticamente aceptables del compuesto de fórmula (1), mezclas racémicas del compuesto de fórmula (1), o el isómero óptico y/o enantiómero correspondiente del compuesto de fórmula (1), y formas polimórficas del compuesto de fórmula (1), así como también formas tautoméricas del compuesto de fórmula (1); siempre que el compuesto de fórmula (1) no sea 1,2,4-triazolo[4,3-a]pirazin-8(7H)-ona sustituido con 7-[(4-clorofenil)metil]-3-metil- (número de registro CAS: 946270-18-4) ni 1,2,4-triazolo[4,3-a]pirazin-8(7H)-ona sustituido con 7-[(4-clorofenil)metil-3-propil- (número de registro CAS: 946237-23-6).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400582 | 2014-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102227A1 true AR102227A1 (es) | 2017-02-15 |
Family
ID=58698606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103269A AR102227A1 (es) | 2014-10-10 | 2015-10-09 | Triazolopirazinonas como inhibidores de pde1 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10150771B2 (es) |
| EP (1) | EP3204387B1 (es) |
| JP (1) | JP6596489B2 (es) |
| KR (1) | KR20170066417A (es) |
| CN (1) | CN106715438B (es) |
| AR (1) | AR102227A1 (es) |
| AU (1) | AU2015329898A1 (es) |
| BR (1) | BR112017006940A2 (es) |
| CA (1) | CA2961986A1 (es) |
| CL (1) | CL2017000817A1 (es) |
| CO (1) | CO2017002708A2 (es) |
| DO (1) | DOP2017000080A (es) |
| EA (1) | EA201790575A1 (es) |
| EC (1) | ECSP17018120A (es) |
| ES (1) | ES2735733T3 (es) |
| IL (1) | IL251420A0 (es) |
| MX (1) | MX2017004510A (es) |
| PE (1) | PE20180024A1 (es) |
| PH (1) | PH12017500621A1 (es) |
| RU (1) | RU2017111888A (es) |
| SG (1) | SG11201702874YA (es) |
| SV (1) | SV2017005419A (es) |
| TN (1) | TN2017000099A1 (es) |
| TW (1) | TW201629064A (es) |
| WO (1) | WO2016055618A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| TW201643167A (zh) * | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| US10034861B2 (en) * | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20170164A1 (ar) | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| AU2017350473A1 (en) * | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| MX390582B (es) | 2016-12-28 | 2025-03-20 | Dart Neuroscience Llc Star | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2) |
| AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| DK3717488T3 (da) | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
| AR113926A1 (es) * | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PT3723807T (pt) * | 2017-12-14 | 2021-11-26 | H Lundbeck As | Tratamentos de associação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) * | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| TW201927784A (zh) * | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| US10766893B2 (en) * | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US11453673B2 (en) * | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
| JP7493460B2 (ja) | 2018-05-25 | 2024-05-31 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| JP2006525966A (ja) | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類 |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| MX2011002340A (es) | 2008-09-08 | 2011-04-04 | Boehringer Ingelheim Int | Pirazolopirimidinas y su uso para el tratamiento de trastornos del snc. |
| JP5813511B2 (ja) * | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| EP2575817A4 (en) * | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
| WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
| JP6051210B2 (ja) * | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| CN107082783B (zh) | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| BR112014031730B1 (pt) | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
| ES2836129T3 (es) | 2013-03-15 | 2021-06-24 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| JP2017527606A (ja) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 三環系誘導体 |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (zh) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
-
2015
- 2015-10-08 TW TW104133183A patent/TW201629064A/zh unknown
- 2015-10-09 CN CN201580052980.2A patent/CN106715438B/zh not_active Expired - Fee Related
- 2015-10-09 US US15/517,348 patent/US10150771B2/en active Active
- 2015-10-09 EP EP15787486.8A patent/EP3204387B1/en active Active
- 2015-10-09 RU RU2017111888A patent/RU2017111888A/ru unknown
- 2015-10-09 TN TN2017000099A patent/TN2017000099A1/en unknown
- 2015-10-09 BR BR112017006940A patent/BR112017006940A2/pt not_active Application Discontinuation
- 2015-10-09 ES ES15787486T patent/ES2735733T3/es active Active
- 2015-10-09 MX MX2017004510A patent/MX2017004510A/es unknown
- 2015-10-09 CA CA2961986A patent/CA2961986A1/en not_active Abandoned
- 2015-10-09 WO PCT/EP2015/073417 patent/WO2016055618A1/en not_active Ceased
- 2015-10-09 KR KR1020177009566A patent/KR20170066417A/ko not_active Withdrawn
- 2015-10-09 AU AU2015329898A patent/AU2015329898A1/en not_active Abandoned
- 2015-10-09 AR ARP150103269A patent/AR102227A1/es unknown
- 2015-10-09 SG SG11201702874YA patent/SG11201702874YA/en unknown
- 2015-10-09 PE PE2017000481A patent/PE20180024A1/es not_active Application Discontinuation
- 2015-10-09 EA EA201790575A patent/EA201790575A1/ru unknown
- 2015-10-09 JP JP2017518482A patent/JP6596489B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-21 DO DO2017000080A patent/DOP2017000080A/es unknown
- 2017-03-22 CO CONC2017/0002708A patent/CO2017002708A2/es unknown
- 2017-03-24 EC ECIEPI201718120A patent/ECSP17018120A/es unknown
- 2017-03-27 IL IL251420A patent/IL251420A0/en unknown
- 2017-03-31 SV SV2017005419A patent/SV2017005419A/es unknown
- 2017-04-04 CL CL2017000817A patent/CL2017000817A1/es unknown
- 2017-04-04 PH PH12017500621A patent/PH12017500621A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106715438B (zh) | 2019-04-12 |
| TW201629064A (zh) | 2016-08-16 |
| JP6596489B2 (ja) | 2019-10-23 |
| WO2016055618A1 (en) | 2016-04-14 |
| SG11201702874YA (en) | 2017-05-30 |
| DOP2017000080A (es) | 2017-05-15 |
| CO2017002708A2 (es) | 2017-06-30 |
| MX2017004510A (es) | 2017-06-28 |
| US20170298072A1 (en) | 2017-10-19 |
| AU2015329898A1 (en) | 2017-03-30 |
| JP2017530173A (ja) | 2017-10-12 |
| ECSP17018120A (es) | 2017-08-31 |
| IL251420A0 (en) | 2017-05-29 |
| EP3204387B1 (en) | 2019-06-12 |
| CL2017000817A1 (es) | 2017-11-03 |
| US10150771B2 (en) | 2018-12-11 |
| KR20170066417A (ko) | 2017-06-14 |
| BR112017006940A2 (pt) | 2018-01-09 |
| ES2735733T3 (es) | 2019-12-20 |
| EP3204387A1 (en) | 2017-08-16 |
| EA201790575A1 (ru) | 2017-07-31 |
| PH12017500621A1 (en) | 2017-09-25 |
| PE20180024A1 (es) | 2018-01-09 |
| SV2017005419A (es) | 2017-06-07 |
| TN2017000099A1 (en) | 2018-07-04 |
| CN106715438A (zh) | 2017-05-24 |
| CA2961986A1 (en) | 2016-04-14 |
| RU2017111888A (ru) | 2018-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102227A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| CL2019002032A1 (es) | Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018). | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| EP3759109C0 (en) | SUBSTITUTED PYRROLIZINE COMPOUNDS AS INHIBITORS OF HEPATITIS B VIRUS REPLICATION | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| EP2964221A4 (en) | COMPOUNDS FOR INHIBITING THE REPEATING ACTIVITY OF A LEUKINARY KINASEENZYME | |
| EA201591491A1 (ru) | Соединения тетрагидропирролотиазина | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EP3472168A4 (en) | CRYSTALLINE FORMS OF A TRIAZOLOPYRIMIDINE COMPOUND | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| EA201591486A1 (ru) | Соединения имидазопиридина | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MX384244B (es) | 4-fenilpiperidinas sustituidas, su preparacion y uso. | |
| AR108109A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| AR102989A1 (es) | Compuestos antibacterianos con acción sobre topoisomerasas | |
| CO2019006220A2 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| IL285721A (en) | Methods of making high enantioselective secondary alcohols | |
| MX2019003545A (es) | Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. | |
| DK3840832T3 (da) | Imidazo[1,2-b]pyridaziner som trk-inhibitorer | |
| AR101155A1 (es) | Quinazolin-thf-aminas halogenadas como inhibidores de pde1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |